Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $324,154.60 in Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 21,049 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $15.40, for a total transaction of $324,154.60. Following the completion of the transaction, the insider directly owned 243,418 shares of the company’s stock, valued at $3,748,637.20. This represents a 7.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Stock Up 0.1%

SiBone stock opened at $15.48 on Friday. The firm has a market capitalization of $671.68 million, a P/E ratio of -30.35 and a beta of 0.69. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. SiBone has a twelve month low of $12.49 and a twelve month high of $21.89. The stock’s fifty day simple moving average is $17.84 and its 200-day simple moving average is $16.83.

Hedge Funds Weigh In On SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd acquired a new stake in SiBone during the fourth quarter worth approximately $29,000. Royal Bank of Canada boosted its holdings in shares of SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after buying an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after buying an additional 1,941 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in SiBone during the 3rd quarter worth $39,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in SiBone during the 4th quarter worth $53,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on SIBN. TD Cowen raised SiBone to a “strong-buy” rating in a research report on Tuesday, January 27th. Morgan Stanley upped their target price on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Truist Financial boosted their price target on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Canaccord Genuity Group increased their price objective on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, SiBone has an average rating of “Moderate Buy” and an average price target of $24.33.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.